Literature DB >> 19190176

Ethical considerations in pediatric oncology phase I clinical trials according to The Belmont Report.

Wendy J Haylett1.   

Abstract

Whether to suggest enrollment of pediatric oncology patients with advanced or refractory disease into a Phase I clinical trial may present a significant ethical dilemma for health care professionals. Phase I trials are experimental and unpredictable by nature, yet health care professionals must ensure the trial's therapeutic intent as well as address the many vulnerabilities of the child with terminal cancer. After reviewing the role and phases of clinical research in pediatric oncology, this article discusses ethical considerations in Phase I clinical trials according to The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects in Research and discusses specific applications of these key ethical principles.

Entities:  

Mesh:

Year:  2009        PMID: 19190176     DOI: 10.1177/1043454208328764

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN: 1043-4542            Impact factor:   1.636


  4 in total

1.  Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer.

Authors:  Deena R Levine; Liza-Marie Johnson; Belinda N Mandrell; Jie Yang; Nancy K West; Pamela S Hinds; Justin N Baker
Journal:  Cancer       Date:  2014-12-29       Impact factor: 6.860

Review 2.  The complexity of consenting to clinical research in phase I pediatric cancer studies.

Authors:  Tal Schechter; Ronald Grant
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

3.  A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.

Authors:  Julia W Cohen; Srivandana Akshintala; Eli Kane; Helen Gnanapragasam; Brigitte C Widemann; Seth M Steinberg; Nirali N Shah
Journal:  Oncologist       Date:  2020-01-14

4.  Communication about the risks and benefits of phase I pediatric oncology trials.

Authors:  Rebecca A Hazen; Stephen Zyzanski; Justin N Baker; Dennis Drotar; Eric Kodish
Journal:  Contemp Clin Trials       Date:  2015-01-29       Impact factor: 2.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.